Roche Agenda For 2001 Includes Kytril NDA For Post-Op Use, Pegasys Launch
Executive Summary
Roche plans to file an NDA during 2001 for use of the anti-emetic Kytril in post-operative nausea and vomiting, the company said during a recent analysts meeting in Basel.
You may also be interested in...
Xenical Diabetes sNDA Withdrawn; FDA, Roche Disagree On Wording
Roche is contemplating how to pursue a type 2 diabetes indication for Xenical after withdrawing a supplemental NDA for the claim
Xenical Diabetes sNDA Withdrawn; FDA, Roche Disagree On Wording
Roche is contemplating how to pursue a type 2 diabetes indication for Xenical after withdrawing a supplemental NDA for the claim
Roche Sees Pegasys Approval Delay Until 2002, But With Broader Indication
Roche's "current expectation" for the pegylated interferon product Pegasys is that it will be approved in the first half of 2002, with an indication covering both monotherapy and combination use.